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a  b  s  t  r  a  c  t
Introduction:  The  epidermal  growth  factor  receptor  (EGFR)  tyrosine-kinase  inhibitor  erlotinib  is  associ-
ated with survival  beneﬁts  in  patients  with  EGFR  mutation-positive  non-small-cell  lung  cancer  (NSCLC).
This  phase  II,  single-arm  study examined  the  efﬁcacy  and  safety  of  ﬁrst-line  erlotinib  in Japanese  patients
with  EGFR  mutation-positive  NSCLC.
Methods:  Eligible  patients  received  erlotinib  150  mg/day  until  disease  progression  or unacceptable  tox-
icity.  The  primary  endpoints  were  progression-free  survival  (PFS)  and  safety.
Results: A  high  degree  of  concordance  was  observed  between  different  mutation  testing  methodologies,
suggesting  feasibility  of early,  rapid detection  of EGFR  mutations.  Median  PFS  was 11.8  months  (95%
conﬁdence  interval  [CI]:  9.7–15.3)  at data cut-off  (1 June  2012)  (n =  102).  Exon  19 deletions  seemed  to  be
associated  with  longer  PFS  compared  with  L858R  mutations;  T790M  mutations  were  tentatively  linkedon-small-cell lung cancer (NSCLC)
hase II
GFR testing
with  shorter  PFS.  The  safety  proﬁle  was  as expected:  rash  (any  grade;  83%)  and  diarrhea  (any  grade;  81%)
were most  common.  Six  interstitial  lung  disease  (ILD)-like  cases  were  reported,  and  5  were  conﬁrmed  as
ILD-like  events  by  the extramural  committee.  Two  patients  died of  treatment-related  pneumonitis  (JAPIC
Clinical  Trials  Information  number:  Japic  CTI-101085).
Conclusion:  Erlotinib  should  be  considered  for ﬁrst-line  treatment  in  this  subset  of  Japanese  patients,  with
close  monitoring  for  ILD-like  events.
2013© ∗ Corresponding author at: Department of Thoracic Oncology National Cancer
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1. Introduction
Non-small-cell lung cancer (NSCLC) remains a signiﬁcant global
health burden, with high mortality and poor prognosis for patients
diagnosed at an advanced stage. Erlotinib is an epidermal growth
factor receptor (EGFR) tyrosine-kinase inhibitor (TKI), which has
Open access under CC BY license.been approved for the treatment of advanced NSCLC. Originally
approved as second- or third-line treatment in patients refrac-
tory to chemotherapy, erlotinib showed overall survival (OS)
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lacebo in a large phase III trial (OS: 6.7 vs. 4.7 months, respectively,
azard ratio [HR] = 0.7, 95% conﬁdence interval [CI]: 0.58–0.85,
 < 0.001; PFS: 2.2 vs. 1.8 months, respectively, HR = 0.61, 95% CI:
.51–0.74, p < 0.001) [1]. Further trials have expanded its use to
aintenance therapy (SATURN) [2] and to ﬁrst-line treatment of
GFR mutation-positive disease (OPTIMAL and EURTAC) [3,4]. The
atter 2 studies reported signiﬁcant PFS beneﬁts with erlotinib as
rst-line treatment for EGFR mutation-positive NSCLC compared
ith chemotherapy in Chinese and European populations (OPTI-
AL: 13.1 vs. 4.6 months, respectively, HR = 0.16, 95% CI: 0.10–0.26,
 < 0.0001; EURTAC: 9.7 vs. 5.2 months, respectively, HR = 0.37, 95%
I: 0.25–0.54, p < 0.0001).
Until now, erlotinib has not been prospectively evaluated
n Japanese patients with EGFR mutation-positive NSCLC. This
rospective, phase II, open-label study (JO22903) was  initiated to
btain conﬁrmatory efﬁcacy and safety data in the ﬁrst-line setting
or Japanese patients with EGFR mutation-positive NSCLC, in order
o corroborate data from Chinese and Caucasian populations.
. Materials and methods
.1. Study design and patients
JO22903 was a phase II, multicenter, open-label, non-
andomized study conducted at 25 centers in Japan. Eligible
atients were aged ≥20 years with advanced, untreated, metastatic
stage IIIB/IV), or relapsed NSCLC, with an Eastern Cooperative
ncology Group performance status (ECOG PS) of 0 or 1 and tumors
arboring conﬁrmed activating mutations of EGFR (exon 19 dele-
ion or L858R point mutation in exon 21), with at least 1 measurable
esion according to Response Evaluation Criteria in Solid Tumors
RECIST) version 1.0. Staging was assessed by TNM classiﬁcation
7th edition). The study was carried out in accordance with the Dec-
aration of Helsinki and Japanese Good Clinical Practice guidelines.
he protocol was approved by ethics committees and all patients
ave informed consent for study participation.
.2. Procedures
Eligible patients received oral erlotinib 150 mg/day until disease
rogression (PD) or unacceptable toxicity (Fig. 1). Dose reductions
in 50-mg decrements) and/or interruptions (of up to 2 weeks) were
ermitted to manage adverse events (AEs) related to erlotinib treat-
ent. Treatment was interrupted if interstitial lung disease (ILD)
as suspected; for patients with conﬁrmed ILD diagnosis, erlotinib
as discontinued immediately. In cases of gastrointestinal perfo-
ation or any grade 4 AE, erlotinib was discontinued.
Patients were screened for EGFR mutations in a local or cen-
ral laboratory. In the central laboratory, EGFR mutation status
as determined using Scorpion ARMS [5]. For exploratory anal-
ses, tumor samples were obtained from hospital archives for
Eligibility criteria
• Japanese patients aged  ≥20 years with advanced, unt reated,
metastatic (stage IIIB/IV), or relapsed NSCLC
• ECOG PS 0 or 1
• Tumors harboring activating mutations of EGFR
(confirmed by screening in local or central laboratory)
• ≥1 measurable lesion acco rding to RECIST v 1.0
All eligible patients received 
150 mg/day
oral erlotinib
Treatment continued until 
PD or unacceptable toxicity
Fig. 1. Study design and eligibility criteria. 82 (2013) 109– 114
patients who  were screened in their local laboratory to conﬁrm the
concordance between several local methods and Scorpion ARMS.
In addition, serum samples were collected at screening from all
patients who  provided informed consent to participate in the
exploratory research (n = 95). DNA was isolated from serum with
the QIAmp MinElute Virus Spin kit (Qiagen, Hilden, Germany). Scor-
pion ARMS was  used for EGFR mutation testing for circulating DNA
in the serum.
Tumor response was assessed by an independent review com-
mittee (IRC) using RECIST version 1.0. Tumor response evaluation
was scheduled every 6 weeks. AEs were graded according to
the National Cancer Institute Common Terminology Criteria for
Adverse Events (NCI-CTC AE) version 4.0.
At baseline mandatory lung and abdominal scans (CT/MRI),
brain scans (CT/MRI) and bone scans (bone scintigraphy, PET, CT
and MRI) were performed. During treatment until disease progres-
sion, lung and abdominal scans were mandatory. Brain scans were
required for those patients who revealed brain metastases at base-
line. When conﬁrming complete or partial tumor response, bone
scans were required for patients with bone metastases at baseline.
2.3. Study endpoints
Primary endpoints were PFS, as assessed by an IRC, and safety
proﬁle. Secondary endpoints included overall response rate (ORR),
disease control rate (DCR), and OS. Exploratory analyses examined
concordance between different EGFR mutation testing method-
ologies, and concordance between serum and tumor tissue at
screening. EGFR mutation status alterations in serum before and
after treatment were observed.
2.4. Statistical analyses
The statistical plan assumed a median PFS of 7 months in the
historical control group and 11 months in the erlotinib treatment
group. The primary analysis was  planned for 11 months after the
last patient was enrolled to conﬁrm superiority of erlotinib over
the historical control.
Given an expected median PFS of 11 months, 93 patients were
necessary to provide statistical power of 80% to conﬁrm the superi-
ority of the lower conﬁdence boundary of the observed median PFS
compared with the threshold median PFS of 7 months. The target
sample size was 100 patients, taking into consideration patients
who would prove to be ineligible for the study. For PFS (the pri-
mary efﬁcacy endpoint), OS, and duration of response, median and
95% CIs were estimated using Kaplan–Meier survival methodol-
ogy. CI limits were calculated according to the Greenwood method.
Response rate and DCR were summarized by presenting the rate
and 95% CIs according to Pearson–Clopper.
The analysis of safety parameters (co-primary endpoint) was
descriptive: all AEs were converted to MedDRA preferred terms
and summary tables were produced. For laboratory parameters,
descriptive summary tables or graphs of change over time were
produced.
According to the statistical analysis plan, all patients who
received at least 1 dose of study treatment would be included in
the safety population. The modiﬁed intention-to-treat (ITT) pop-
ulation for the efﬁcacy analysis excluded all patients with major
protocol violations.
3. Results3.1. Patient population
Between 8 April 2010 and 6 October 2010, 103 patients with
conﬁrmed EGFR mutations were enrolled and received erlotinib,
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Table  1
Baseline characteristics for the safety population (n = 103).
Characteristics n (%)






1  54 (52)
Smoking status
Current smoker 7 (7)
Former smoker 37 (36)
Never smoker 59 (57)
Median Brinkman index (range) (n = 44) 580.0 (3–1720)
Type of EGFR mutation
Exon 19 deletion 50 (49)
L858R mutation 51 (50)
L858R mutation + T790M 2 (2)
EGFR mutation in serum (n = 95)
EGFR mutation detected 25 (26)





IIIB  4 (4)
IV  74 (72)




No  78 (76)
Induction or adjuvant chemotherapya
Yes 12 (12)
No  91 (88)
Radiation
Yes  17 (17)
No  86 (84)
Abbreviations: ECOG PS = Eastern Cooperative Oncology Group performance status;








FPatients may  have had prior therapy providing the following conditions were
et: platinum-based chemotherapy: wash-out period of 6 months; non-platinum-
ased chemotherapy: wash-out period of 4 weeks.omprising the safety population. The majority of patients (95/103;
2%) had their samples screened in local practice, while the
emaining 8 (8%) had their samples screened at a central labora-
ory. One patient was excluded from the modiﬁed ITT population
ig. 2. PFS in the modiﬁed ITT population by the follow-up analysis (1 June 2012 data cut-o 82 (2013) 109– 114 111
as they had a major protocol violation after enrollment. The base-
line characteristics for the safety population are shown in Table 1.
At the time of data cut-off for the primary analysis (1 September
2011), 44 patients remained in the study, either on treatment or in
follow-up.
3.2. Efﬁcacy analyses
At the primary analysis (data cut-off 1 September 2011), median
PFS with ﬁrst-line erlotinib was  11.8 months (95% CI: 9.7 to not
reached). The 1-year event-free survival rate was  49% (95% CI:
39–59). Eighty patients had a complete or partial response with
erlotinib, giving an ORR of 78% (complete response: 4 patients; par-
tial response: 76 patients); a further 17 patients had stable disease,
giving a DCR of 95%.
In the follow-up analysis (data cut-off 1 June 2012), the median
PFS was  11.8 months (95% CI: 9.7–15.3) (Fig. 2) and had not changed
after a longer follow-up. The 1-year event-free survival rate was
50% (95% CI: 40–60). The median duration of response was 11.1
months (95% CI: 9.7–13.9). Full response data also did not change
with a follow-up analysis by IRC.
Subgroup analyses of baseline characteristics and PFS are sum-
marized in Fig. 3. All patient subgroups showed favorable PFS
regardless of gender, age, smoking status, disease stage, or type
of EGFR mutation.
Examining the PFS results by EGFR mutation type, i.e., exon
19 deletions vs. L858R point mutations, demonstrated that exon
19 deletions seemed to be associated with longer PFS (Fig. 4a).
Median PFS with exon 19 deletions (n = 50) was 12.5 months (95%
CI: 10.3–16.6), while with L858R mutations (n = 50) it was 11.0
months (95% CI: 6.9–15.2). Two patients whose tumors harbored
the T790M mutation with L858R had poor outcomes, with PFS
of 2.9 and 4.6 months, respectively. It should be noted that it is
impossible to distinguish between prognostic or predictive effects
of different mutations without a control arm. In this study, how-
ever, the 4 patients with complete response to erlotinib all had
tumors with exon 19 deletions (Fig. 4b). Response rate with exon
19 deletions (n = 50) was  84%, while with L858R mutations (n = 50)
it was  76%.
Examining PFS by grade of skin rash determined that higher
grades (grade ≥2) of rash were associated with longer PFS with
erlotinib (Supplementary data, Fig. S1).
Supplementary data associated with this article can be
found, in the online version, at http://dx.doi.org/10.1016/j.lungcan.
2013.07.003.
By the second cut-off date, 28 of 102 patients had died. The
median survival time could not be calculated.
ff). PFS = progression-free survival; ITT = intention-to-treat; CI = conﬁdence interval.




















aFig. 3. Forest plot of subgroup analyses for PFS (1 June 2012 d
.3. Safety analyses
AEs reported in more than 20% of patients in the safety
opulation are presented in Table 2. Two patients died of
reatment-related pneumonitis; in both cases, simultaneous PD
as reported by the investigators. A total of 43 patients required
ose modiﬁcation due to AEs of grade ≥2, the majority of which
ere skin toxicities (n = 22). Ten patients (10%) discontinued
rlotinib due to AEs: ILD or ILD-like events (n = 6), abnormal liver
unction or liver enzyme levels (n = 3), and skin rash (n = 1).
Six ILD-like cases were reported, and 5 cases were conﬁrmed as
LD-like events according to the extramural committee. Three cases
ere grade 1/2, 2 were grade 5, and the 1 unconﬁrmed ILD case was
rade 1. One fatal ILD case that occurred 9 months after treatment
nitiation showed co-existence of aspiration pneumonia. The extra-
ural committee suggested the possibility that ILD developed as
 secondary complication following the aspiration pneumonia. By
able 2
Es occurring in >20% of the safety population (n = 103).
Any grade Grade 1 Grade 2 Grade ≥3
n % n % n % n %
Rash 85 83 27 26 44 43 14 14
Diarrhea 83 81 58 56 24 23 1 1
Dry  skin 79 77 45 44 29 28 5 5
Paronychia 68 66 17 17 50 49 1 1
Pruritus 66 64 36 35 27 26 3 3
Stomatitis 65 63 45 44 19 18 1 1
Decreased appetite 36 35 20 19 13 13 3 3
Nasopharyngitis 34 33 25 24 9 9 – –
ALT  increased 34 33 21 20 5 5 8 8
Alopecia 28 27 27 26 1 1 – –
AST  increased 27 26 19 18 5 5 3 3
T-Bil increased 26 25 11 11 15 15 – –
bbreviations: AEs = adverse events; ALT = alanine aminotransferase; AST = aspartate
minotransferase; T-Bil = total bilirubin. No patient counted here had a grade 4/5
dverse event.t-off). PFS = progression-free survival; CI = conﬁdence interval.
the second cut-off date (1 June 2012), no further ILD or ILD-like
events had been observed.
3.4. Exploratory analyses
This study offered an opportunity to assess concordance across
different methodologies. Forty archive samples from local testing
were assessed at a central laboratory; for 38 of the samples (95%),
the central laboratory testing produced identical results to the orig-
inal local laboratory testing. Baseline serum samples were available
from 95 patients, and EGFR mutations were detected in 25 patients
(centrally by Scorpion ARMS), which showed the same mutation
type as the tumor (Supplementary data, Tables S1–S3 and Fig. S1).
No patients showed T790 M mutation in serum at baseline. In the
serum samples obtained from the 2 patients whose tumors showed
T790 M at baseline, no mutation at baseline was  observed in the
serum sample.
Supplementary data associated with this article can be
found, in the online version, at http://dx.doi.org/10.1016/j.lungcan.
2013.07.003.
4. Discussion
JO22903 is the ﬁrst prospective study to investigate erlotinib
for the ﬁrst-line treatment of EGFR mutation-positive NSCLC in
Japanese patients. In this study, the lower boundary of the 95%
CI was  9.7 months, which was  longer than the 7 months thresh-
old value, and the median PFS reached 11.8 months in this patient
population.
The median PFS of 11.8 months is similar to that reported
for Chinese patients with EGFR mutation-positive disease in the
phase III OPTIMAL study, which was 13.1 months [3]. The PFS of
both the present study and OPTIMAL were slightly higher than
the PFS in European patients with EGFR mutation-positive NSCLC
(9.7 months) [4]. Geﬁtinib has also been evaluated as a ﬁrst-line
treatment for NSCLC in Asian patients. According to a retrospective
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Fig. 4. (a) PFS according to type of EGFR mutation (1 June 2012 data cut-off). PFS = progression-free survival; EGFR = epidermal growth factor receptor. (b) Waterfall plot of


























Jaseline. The dashed line represents partial response indicated by 30% tumor shrin
esponse; PD = progressive disease; SD = stable disease.
nalysis of the IPASS study by EGFR mutation status, the subgroup
f patients with EGFR mutation-positive NSCLC had a median PFS
f 9.5 months [6]. In addition, 2 Japanese studies in patients with
GFR mutation-positive NSCLC showed median PFS of 9.2 and 10.8
onths (WJTOG3405 and NEJ002, respectively) [7,8]. Again, these
edians are similar to that achieved in the present study (Supple-
entary data, Table S4).
Supplementary data associated with this article can be
ound, in the online version, at http://dx.doi.org/10.1016/j.lungcan.
013.07.003.
According to an analysis of data from an online tumor reg-
stry examining ﬁrst-line EGFR TKI treatment, all efﬁcacy outcomes
ORR, time to progression, OS) were better in patients with exon 19
eletions compared with L858R mutations [9]. In the EURTAC study,
 similar trend was observed. However, this association has not
een observed in geﬁtinib studies (IPASS, NEJ002 and WJTOG3405)
6–8]. The present study also showed longer PFS in patients with
xon 19 deletions rather than L858R mutations (median PFS of 12.5
nd 11.0 months, respectively). This study suggests that the dif-
erence seen in efﬁcacy outcomes between patients with exon 19
eletions mutations and those with L858R is speciﬁc to erlotinib,
s also demonstrated in the EURTAC study [4].
The safety proﬁle of erlotinib in this study was as expected,
ith rash and diarrhea being the most common AEs. Although
atients in this study received treatment with erlotinib for a
onger duration than patients treated in the second- and third-line
apanese studies, due to the longer PFS, the common AEs were EGFR = epidermal growth factor receptor; ORR = overall response rate; PR = partial
similar to previous studies [10,11]. No long-term toxicity was
observed.
Six out of the total 108 patients included in the erlotinib
second-/third-line Japanese studies were conﬁrmed to have
EGFR mutations [10,11]. Common AEs were similar between
patients with EGFR mutation-positive NSCLC receiving ﬁrst-line or
second-/third-line erlotinib.
Six occurrences (6%) of treatment-related ILD or ILD-like events
were reported by investigators, among which 5 (5%) were con-
ﬁrmed as ILD cases but 1 case was  denied by an extramural
committee. Two (2%) of these 5 were classiﬁed as severe and
resulted in death. The WJTOG3405 and NEJ002 studies reported
an ILD incidence of 2% (2/87, with 1 fatal case) and 5.3% (6/114
patients, with 1 fatal case), respectively [7,8]. According to a recent
large-scale surveillance study of erlotinib in the second-/third-line
treatment of Japanese NSCLC patients, the incidence of ILD was
4.5% and the mortality rate was  1.6% [12]. Thus, the incidence of
ILD/ILD-like events in the JO22903 study was  generally as expected.
Close monitoring of Japanese patients for symptoms of ILD and
immediate cessation of erlotinib therapy on diagnosis is recom-
mended.
In this study, the incidence of grade 3 rash was 14%, compared
with 2% in the WJTOG3405 study of geﬁtinib [7] and 5% in the
NEJ002 study of geﬁtinib [8]. A higher incidence of grade 3 rash was
observed in this study; however, with the exception of 1 patient, it
was possible for patients to continue receiving erlotinib with dose
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The incidence of grade ≥3 alanine aminotransferase (ALT)
nd aspartate aminotransferase (AST) elevation was 8% and 3%,
espectively. In addition, the incidence of grade ≥3 abnormal
epatic function or liver disorder was 4% in this study. Three
atients were withdrawn from erlotinib treatment due to abnormal
iver function or liver enzyme levels. Despite these 3 patients show-
ng normal enzyme levels for AST and ALT at screening, they showed
evere changes approximately 1 month after treatment initiation.
A total of 43 patients required dose modiﬁcation due to AEs,
nd 10 patients (10%) discontinued erlotinib in this study. In the
JTOG3405 study, 14 of 87 patients (16%) discontinued geﬁtinib
ue to AEs. Although the safety proﬁle of these 2 EGFR TKIs seem
o be slightly different, this study suggests that erlotinib has sim-
lar tolerability to geﬁtinib in the ﬁrst-line treatment of Japanese
atients with EGFR mutation-positive NSCLC.
A ﬁnal exploratory aspect of this study concerned the EGFR
utation assessment for circulating DNA in serum. Twenty ﬁve
26%) of 95 patients showed EGFR mutation-positive disease
ssessed by Scorpion ARMS. This 26% detection rate was  lower
han in the EURTAC study (58 [53%] of 109 serum samples) [4],
nd seemed to be insufﬁcient for the screening test. However,
lthough low detection rates were seen in serum samples, both
tudies showed high concordance (∼100%) between serum and
umor samples at baseline. Thus, we cannot make deﬁnitive con-
lusions regarding the utility of serum samples as EGFR mutation
ssessment specimens.
. Conclusions
This study indicates that early, local testing of EGFR muta-
ion status is feasible and can reliably identify patients with EGFR
utation-positive NSCLC. The reported PFS in this study of Japanese
SCLC patients was 11.8 months with ﬁrst-line erlotinib treatment,
hich is comparable to PFS outcomes seen with this agent in other
GFR mutation-positive populations, conﬁrming that erlotinib can
rovide a good PFS beneﬁt in this subgroup. Erlotinib was  generally
ell tolerated, although 6 (of 103) patients reported ILD/ILD-like
vents and 5 were conﬁrmed by an extramural committee, con-
rming that ILD remains a risk with EGFR TKI treatment in Japanese
atients. Continued monitoring for symptoms of ILD and prompt
ction on diagnosis is recommended. Despite this, the efﬁcacy and
anageable safety proﬁle demonstrated by erlotinib in this study
onﬁrms that erlotinib should be recommended for the ﬁrst-line
reatment of Japanese NSCLC patients with EGFR mutation-positive
isease.
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